PRME
Price
$1.90
Change
-$0.19 (-9.13%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
314.79M
59 days until earnings call
RCKT
Price
$8.21
Change
-$0.38 (-4.42%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
935.14M
62 days until earnings call
Ad is loading...

PRME vs RCKT

Header iconPRME vs RCKT Comparison
Open Charts PRME vs RCKTBanner chart's image
Prime Medicine
Price$1.90
Change-$0.19 (-9.13%)
Volume$33.01K
Capitalization314.79M
Rocket Pharmaceuticals
Price$8.21
Change-$0.38 (-4.42%)
Volume$61K
Capitalization935.14M
PRME vs RCKT Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. RCKT commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and RCKT is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (PRME: $2.08 vs. RCKT: $8.59)
Brand notoriety: PRME and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 182% vs. RCKT: 76%
Market capitalization -- PRME: $314.79M vs. RCKT: $935.14M
PRME [@Biotechnology] is valued at $314.79M. RCKT’s [@Biotechnology] market capitalization is $935.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileRCKT’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • RCKT’s FA Score: 0 green, 5 red.
According to our system of comparison, both PRME and RCKT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 3 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 3 bullish, 6 bearish.
  • RCKT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а -6.94% price change this week, while RCKT (@Biotechnology) price change was -2.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.64%. For the same industry, the average monthly price growth was -8.11%, and the average quarterly price growth was -7.39%.

Reported Earning Dates

PRME is expected to report earnings on May 09, 2025.

RCKT is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+0.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($935M) has a higher market cap than PRME($315M). PRME YTD gains are higher at: -28.767 vs. RCKT (-31.663). PRME has higher annual earnings (EBITDA): -207.13M vs. RCKT (-247.25M). RCKT has more cash in the bank: 236M vs. PRME (176M). RCKT has less debt than PRME: RCKT (25.6M) vs PRME (41.2M). PRME has higher revenues than RCKT: PRME (800K) vs RCKT (0).
PRMERCKTPRME / RCKT
Capitalization315M935M34%
EBITDA-207.13M-247.25M84%
Gain YTD-28.767-31.66391%
P/E RatioN/AN/A-
Revenue800K0-
Total Cash176M236M75%
Total Debt41.2M25.6M161%
FUNDAMENTALS RATINGS
PRME vs RCKT: Fundamental Ratings
PRME
RCKT
OUTLOOK RATING
1..100
6454
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
9291
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (34) in the Biotechnology industry is in the same range as PRME (49) in the null industry. This means that RCKT’s stock grew similarly to PRME’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that RCKT’s stock grew similarly to PRME’s over the last 12 months.

RCKT's SMR Rating (94) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that RCKT’s stock grew similarly to PRME’s over the last 12 months.

RCKT's Price Growth Rating (91) in the Biotechnology industry is in the same range as PRME (92) in the null industry. This means that RCKT’s stock grew similarly to PRME’s over the last 12 months.

RCKT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that RCKT’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMERCKT
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 21 days ago
77%
Bullish Trend 21 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WISIX12.75N/A
N/A
William Blair International Sm Cap Gr I
GCVRX23.23N/A
N/A
Goldman Sachs Large Cp Val Insghts R
GUXPX5.61N/A
N/A
Gabelli Utilities C
HUDEX23.20N/A
N/A
Huber Large Cap Value Inst
PFRSX29.25N/A
N/A
Principal Real Estate Securities Fd R6

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-13.33%
CRSP - PRME
64%
Loosely correlated
-4.81%
NTLA - PRME
58%
Loosely correlated
-8.60%
BEAM - PRME
57%
Loosely correlated
-9.80%
RXRX - PRME
55%
Loosely correlated
-7.06%
ABCL - PRME
53%
Loosely correlated
-5.36%
More

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with NTLA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
-2.05%
NTLA - RCKT
53%
Loosely correlated
-8.60%
AXON - RCKT
52%
Loosely correlated
-2.08%
DNLI - RCKT
52%
Loosely correlated
-10.43%
PRME - RCKT
52%
Loosely correlated
-13.33%
RGNX - RCKT
51%
Loosely correlated
-5.21%
More